BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1848799)

  • 1. Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.
    Grimm EA; Bruner JM; Carinhas J; Köppen JA; Loudon WG; Owen-Schaub L; Steck PA; Moser RP
    Cancer Immunol Immunother; 1991; 32(6):391-9. PubMed ID: 1848799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS; Whiteside TL; Kanbour A; Herberman RB
    J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
    Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
    Cancer Immunol Immunother; 1992; 34(4):241-51. PubMed ID: 1311218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.
    Shimizu Y; Iwatsuki S; Herberman RB; Whiteside TL
    Cancer Immunol Immunother; 1991; 32(5):280-8. PubMed ID: 1847844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
    Koo AS; Tso CL; Shimabukuro T; Peyret C; deKernion JB; Belldegrun A
    J Immunother (1991); 1991 Oct; 10(5):347-54. PubMed ID: 1790142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
    Peyret C; Bochner BH; Lee TY; Koo AS; deKernion JB; Belldegrun A
    J Surg Res; 1992 Dec; 53(6):602-9. PubMed ID: 1494294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
    Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
    Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-12 augments the generation of autologous tumor-reactive CD8+ cytotoxic T lymphocytes from tumor-infiltrating lymphocytes.
    Kuge S; Watanabe K; Makino K; Tokuda Y; Mitomi T; Kawamura N; Habu S; Nishimura T
    Jpn J Cancer Res; 1995 Feb; 86(2):135-9. PubMed ID: 7730135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.
    Facchetti P; Prigione I; Ghiotto F; Tasso P; Garaventa A; Pistoia V
    Cancer Immunol Immunother; 1996 Mar; 42(3):170-8. PubMed ID: 8640845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating CD3- NK cells are more effective than CD3+ T cells in killing autologous melanoma cells.
    Azogui O; Avril MF; Margulis A; Guillard M; Caillou B; Prade M
    J Invest Dermatol; 1991 Sep; 97(3):425-9. PubMed ID: 1831465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
    Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E
    Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.